MedTrace Logo

Taldefgrobep Alfa in Adults With Overweight and Obesity

NCT07281495 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-03-20

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.

Conditions

Interventions

DRUG

Taldefgrobep Alfa

Subcutaneous injection administered once each week

DRUG

Placebo

Subcutaneous injection (matching placebo) administered once each week

DRUG

Taldefgrobep Alfa

Subcutaneous injection administered once every 4 weeks

DRUG

Placebo

Subcutaneous injection (matching placebo) administered once every 4 weeks

Sponsors & Collaborators

  • Biohaven Therapeutics Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-24
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07281495 on ClinicalTrials.gov